This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I40 (acute myocarditis) | Special Copayment Reduction: V192 (special copayment reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Viral myocarditis, infectious myocarditis, isolated myocarditis, acute lymphocytic myocarditis, Viral myocarditis, Fulminant myocarditis |
| C. Adult onset | Can occur at any age but most common in young and middle-aged adults (20–50 years). About 1.5–2 times more common in men than in women; symptoms appear within days to weeks after a preceding viral infection. |
| 1. History | Recognition of myocarditis in the 19th century, establishment of the Dallas criteria (1987), the 2018 revision of the Lake Louise criteria for cardiac MRI, and the 2024 ACC expert consensus pathway |
| 2. Causes | Viruses (coxsackie B, adeno, parvovirus B19, HHV-6, SARS-CoV-2), bacteria, immune checkpoint inhibitors, autoimmunity, drugs |
| 3. Genetics | Associations with HLA-DR4 and HLA-DQ8; rare genetic predisposition to giant cell myocarditis; dystrophin gene variants and myocardial vulnerability |
| 4. General epidemiology | Annual incidence 10–22/100,000; myocarditis accounts for about 5–12% of sudden deaths at age 45 or younger; mRNA vaccine–related myocarditis emerged after COVID-19 |
| 5. Pathophysiology | Three stages: direct viral injury → T cell– and cytokine-mediated autoimmunity → chronic inflammation, fibrosis and dilated cardiomyopathy |
| 6. Symptoms | Chest pain (with accompanying pericarditis), dyspnea, palpitations, fatigue; prodromal viral infection symptoms; cardiogenic shock in fulminant myocarditis |
| 7. Signs | Tachycardia, diminished heart sounds, S3 gallop, pericardial friction rub (with accompanying pericarditis); cardiogenic shock: hypotension, pulmonary edema, reduced peripheral perfusion |
| 8. Screening | Consider myocarditis with chest pain, myocardial injury or arrhythmia at a young age; stepwise ECG, troponin, echocardiography and cardiac MRI |
| 9. Diagnosis | Cardiac MRI (2018 Lake Louise criteria: combined T1 and T2), endomyocardial biopsy (Dallas/immunohistochemical criteria), ECG, viral testing |
| 10. Treatment | Activity restriction, guideline-directed medical therapy for heart failure (GDMT); fulminant: mechanical circulatory support (IABP, ECMO, Impella); immunosuppression for specific forms |
| 11. Prognosis | Most recover spontaneously (about 50%); about 25% have persistent left ventricular dysfunction; giant cell and eosinophilic myocarditis are poor |
| 12. Prevention | Prevention of viral infection (influenza and COVID-19 vaccination); avoid competitive sports during recovery from myocarditis; early diagnosis and treatment |
| 13. References | Caforio ALP et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis … and 9 other papers |
Historical recognition of myocarditis dates back to the 19th century. In 1837 Jean-Nicolas Corvisart first systematically described inflammatory disease of the heart muscle, but at that time the distinction from pericardial or endocardial disease, rather than the myocardium itself, was not clear. Until the 1980s, the diagnosis of myocarditis relied mainly on autopsy findings or clinical presumption.
With the publication of the Dallas criteria (histological criteria) in 1987, histological diagnosis by endomyocardial biopsy was standardized. The Dallas criteria set the simultaneous confirmation of inflammatory cell infiltration and myocyte injury in the biopsy specimen as the basis for diagnosing myocarditis, but limitations in the reproducibility and sensitivity of these criteria were repeatedly pointed out thereafter. In particular, because of sampling error in myocardial biopsy, even myocarditis strongly suspected clinically often came back negative on biopsy, highlighting the need for noninvasive diagnostic methods.
In the 21st century, cardiac magnetic resonance imaging (Cardiac MRI, CMR) emerged as the key tool for diagnosing myocarditis. The first Lake Louise criteria were published in 2009, establishing a system to confirm myocardial inflammation noninvasively by combining three criteria, including T2-weighted imaging and early and late gadolinium enhancement (LGE). In 2018, revised Lake Louise criteria including T1 mapping and T2 mapping were published, greatly improving diagnostic sensitivity and specificity. In 2024 the American College of Cardiology (ACC) published an Expert Consensus Decision Pathway on the diagnosis and management of myocarditis, establishing a modern framework for diagnosis and treatment.
After the COVID-19 pandemic, as cases of myocarditis following SARS-CoV-2 infection and mRNA COVID-19 vaccination were reported, social and medical interest in myocarditis increased greatly. In particular, mRNA vaccine–related myocarditis tends to occur mainly in young men within a few days after the second dose, and most cases have been reported as mild with spontaneous recovery.
The most common cause of acute myocarditis is viral infection, accounting for more than about 50% of cases. Historically, Coxsackievirus B was known as the main cause, but today parvovirus B19 (PVB19) and human herpesvirus 6 (HHV-6) are most often detected in adults. A variety of viruses can be responsible, including adenovirus, enterovirus, cytomegalovirus (CMV), Epstein-Barr virus (EBV), influenza A/B and SARS-CoV-2. HIV infection increases the risk of myocarditis through direct infection or immune-mediated mechanisms.
Bacterial myocarditis is rare, but causes include Borrelia burgdorferi (Lyme disease), Brucella, diphtheria toxin, chlamydia and rickettsia. Lyme myocarditis is characteristically accompanied by conduction disturbances (atrioventricular block). Immune checkpoint inhibitor (ICI)–related myocarditis is an important adverse drug reaction that has risen sharply in recent years and is one of the most dangerous forms of myocarditis, with mortality reaching about 27–50%. Its incidence is highest with combination therapy of a CTLA-4 inhibitor (ipilimumab) and a PD-1/PD-L1 inhibitor (nivolumab, pembrolizumab). Other causes include autoimmune diseases (SLE, rheumatoid arthritis, Wegener's granulomatosis), drug toxicity (anthracyclines, clozapine, cocaine), post–radiation therapy and toxins (insect venom, scorpion venom).
Genetic susceptibility to acute myocarditis has been relatively little studied, but several important genetic associations are known. Studies of HLA associations have reported that HLA-DR4 and HLA-DQ8 are related to susceptibility to viral myocarditis. Coxsackievirus B infects through CAR (Coxsackievirus and Adenovirus Receptor) on the cardiomyocyte surface, and the expression level of this receptor and related gene polymorphisms may influence susceptibility.
Giant cell myocarditis is a rare form of myocarditis with a very poor prognosis; autoimmune mechanisms are considered important, and an association with HLA-DQ8 has been reported. It can also accompany thymoma, inflammatory bowel disease, autoimmune thyroid disease and others, implicating a genetic background of systemic autoimmune predisposition. In patients with Duchenne/Becker muscular dystrophy caused by dystrophin gene variants, the myocardium is known to be more vulnerable to viral injury. Studies have also found that patients with variants in sarcomere proteins (TTN, MYH7, SCN5A, etc.) have a higher risk of progression to dilated cardiomyopathy after myocarditis.
The exact incidence of acute myocarditis varies with differences in diagnostic criteria and methods, but it is generally estimated at about 10–22 per 100,000 population per year. However, mild or atypical cases often go undiagnosed, so the actual incidence is likely higher. Autopsy studies find histological evidence of myocarditis in about 1–9% of the general population.
It can occur at any age but is most common in young and middle-aged adults (20s–40s). It occurs about 1.5–2 times more often in men than in women. Myocarditis is known to account for about 5–12% of sudden deaths in young people under 45 and is closely associated with sudden death in competitive athletes. Seasonally, incidence tends to rise in autumn and spring, when viral infections increase.
Since the COVID-19 pandemic, cases of myocarditis after SARS-CoV-2 infection have increased, and autopsies of severe COVID-19 patients have shown a high rate of myocardial involvement. Myocarditis after mRNA COVID-19 vaccination (BNT162b2, mRNA-1273) has been reported mainly in males aged 12–30, especially within 7 days after the second dose, at an incidence of about 1–10 cases per 100,000 doses. Most cases are mild and recover spontaneously, but some severe cases have also been reported.
The pathogenesis of viral myocarditis is divided into three stages. In stage 1 (acute viral entry, days 0–3), the virus enters cardiomyocytes through cell surface receptors (e.g., CAR, DAF). Viral replication occurs and cardiomyocyte injury results from direct cytotoxicity (cytopathic effect). Innate immune responses (interferon signaling, NK cells) are activated to try to contain viral spread.
In stage 2 (autoimmune activation, days 4–14), the adaptive immune response unfolds in earnest. T cells (CD4+, CD8+) and macrophages infiltrate the myocardium, and various inflammatory mediators (TNF-α, IL-1β, IL-6, IFN-γ) are secreted. Through molecular mimicry, autoantibodies form against myocardial proteins structurally similar to viral proteins (myosin, troponin, etc.), causing autoimmune myocardial injury. At this stage, it can progress to "autoimmune myocarditis," in which the autoimmune response persists even after the virus has effectively been cleared.
In stage 3 (recovery or chronic phase), the disease proceeds to one of two outcomes. If the immune response is effectively regulated, myocardial inflammation subsides and function recovers. If, on the other hand, the autoimmune response and fibrotic process persist, they lead to chronic myocardial inflammation and myocardial remodeling, progressing to dilated cardiomyopathy (DCM). About 9–16% of newly diagnosed DCM is estimated to result from prior myocarditis.
The clinical symptoms of acute myocarditis are highly variable, with a broad spectrum ranging from mild, asymptomatic or slight chest pain to cardiogenic shock from fulminant myocarditis. The most common symptom triad is chest pain, dyspnea and palpitations. With accompanying pericarditis, chest pain is characteristically sharp, positional and pleuritic, while chest pain from cardiomyocyte injury can resemble acute myocardial infarction.
In most patients, prodromal viral infection symptoms (fever, sore throat, myalgia, gastrointestinal symptoms) can be identified 1–4 weeks before the onset of myocarditis symptoms. Palpitations, dizziness or syncope due to arrhythmia may be the first symptoms, and in some cases sudden death from idiopathic ventricular tachycardia or ventricular fibrillation is the first presentation. Fulminant myocarditis progresses rapidly within hours to days to cardiogenic shock, complete atrioventricular block, ventricular fibrillation and the like, threatening life and requiring immediate mechanical circulatory support.
Physical examination findings in acute myocarditis vary with severity and accompanying lesions. In mild cases there may be no specific findings other than tachycardia (increased resting heart rate). In moderate or more severe cases, tachycardia is prominent, heart sounds are diminished, and an S3 gallop due to left ventricular dysfunction may be heard at the apex. With accompanying pericarditis (myopericarditis), a pericardial friction rub is heard at the lower left sternal border. An irregular heartbeat due to atrial fibrillation or premature ventricular beats, or bradycardia due to conduction disturbances, may be observed.
With progression to severe heart failure, signs of pulmonary edema (bilateral crackles, tachypnea), elevated jugular venous pressure, peripheral edema, hypotension and reduced peripheral perfusion (cold, clammy skin, altered consciousness) appear. Fulminant myocarditis is accompanied by all the signs of cardiogenic shock, and survival is often difficult without mechanical circulatory support via a ventricular assist device (VAD) or ECMO.